Clinical experience with vascular endothelial growth factor (VEGF) and vascular endothelial
growth factor receptor (VEGFR) targeting angiogenesis inhibitors is rapidly increasing, and …

The therapeutic potential of targeting the tumor vascular supply is now widely recognized.
Intense research and development activity has resulted in a variety of investigational agents …

PURPOSE The benefit of neoadjuvant chemoradiotherapy in resectable and borderline
resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial …

PURPOSE Preoperative chemoradiotherapy may improve the radical resection rate for
resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven …

Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a
Randomized Phase III Trial - PMC Back to Top Skip to main content NIH NLM Logo Access keys …

Neuroendocrine tumors (NETs) originate from the neuroendocrine cell system in the
bronchial and gastrointestinal tract and can produce hormones leading to distinct clinical …

Purpose: To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and
clinical activity of E7107 administered as 5-minute bolus infusions on days 1, 8, and 15 in a …

Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to
sustained suppression of MAPK signaling and suppressed tumor growth in BRAF V600E …

Metastatic and locally-advanced neuroendocrine neoplasms (aNEN) form clinically and
genetically heterogeneous malignancies, characterized by distinct prognoses based upon …

Abstract Background PDGFRA D842V mutations occur in 5–10% of gastrointestinal stromal
tumours (GISTs), and previously approved tyrosine kinase inhibitors (TKIs) are inactive …